All In Biotech

Drug Trial Radar · NCT07805954

Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients With Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Aug 28, 2026

Primary completion

Mar 2029

Study completion Apr 2030

Sponsor

Lead sponsor
Revolution Medicines, Inc.Industry
Sponsor type
Industry
First posted
Sep 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy of combination therapy with two investigational RAS(ON) inhibitors (daraxonrasib and zoldonrasib) compared to chemotherapy.

Conditions

  • Pancreatic Cancer
  • Pancreatic Cancer Metastatic
  • PDAC
  • PDAC - Pancreatic Ductal Adenocarcinoma
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Pancreatic Adenocarcinoma Metastatic
  • Pancreatic Adenocarcinoma
  • Pancreatic Adenosquamous Carcinoma

Interventions

  • daraxonrasibDrug

    oral tablets

  • gemcitabineDrug

    intravenous (IV) infusion

  • nab-paclitaxelDrug

    IV infusion

  • zoldonrasibDrug

    oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS)Time frame: Up to approximately 4 years
  2. Overall survival (OS)Time frame: Up to approximately 4 years

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona

    Phoenix, Arizona · Recruiting

  • HonorHealth Research Institute

    Scottsdale, Arizona · Recruiting

  • Mayo Clinic Florida

    Jacksonville, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Mayo Clinic Rochester

    Rochester, Minnesota · Recruiting

  • Rhode Island Hospital

    Providence, Rhode Island · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.